Pages that link to "Q33740879"

The following pages link to 18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons (Q33740879):

Displaying 42 items.

• The relevance of beta-amyloid on markers of Alzheimer's disease in clinically normal individuals and factors that influence these associations (Q26830467) (← links)
• Genetic heterogeneity in Alzheimer disease and implications for treatment strategies (Q26995802) (← links)
• Mapping 3-year changes in gray matter and metabolism in Aβ-positive nondemented subjects (Q34498348) (← links)
• The evolution of preclinical Alzheimer's disease: implications for prevention trials (Q34849048) (← links)
• Imaging brain effects of APOE4 in cognitively normal individuals across the lifespan (Q35229601) (← links)
• Arterial spin labeling imaging reveals widespread and Aβ-independent reductions in cerebral blood flow in elderly apolipoprotein epsilon-4 carriers (Q36692478) (← links)
• Cascading network failure across the Alzheimer's disease spectrum (Q36722181) (← links)
• Different partial volume correction methods lead to different conclusions: An (18)F-FDG-PET study of aging (Q36854032) (← links)
• FDG-PET and Neuropsychiatric Symptoms among Cognitively Normal Elderly Persons: The Mayo Clinic Study of Aging (Q37169159) (← links)
• Is amyloid-β harmful to the brain? Insights from human imaging studies (Q37188315) (← links)
• Brain alterations and clinical symptoms of dementia in diabetes: aβ/tau-dependent and independent mechanisms (Q38253639) (← links)
• FDG-PET Contributions to the Pathophysiology of Memory Impairment. (Q38576278) (← links)
• Heterogeneity in Suspected Non-Alzheimer Disease Pathophysiology Among Clinically Normal Older Individuals (Q38829043) (← links)
• Cerebral hypoperfusion and glucose hypometabolism: Key pathophysiological modulators promote neurodegeneration, cognitive impairment, and Alzheimer's disease (Q38879090) (← links)
• Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology (Q38893744) (← links)
• Biomarkers for Early Diagnosis of Alzheimer's Disease in the Oldest Old: Yes or No? (Q39258299) (← links)
• Alzheimer's disease and metabolic syndrome: A link from oxidative stress and inflammation to neurodegeneration. (Q39398227) (← links)
• Alzheimer's Disease Genetic Risk Factor APOE-ε4 Also Affects Normal Brain Function (Q39873829) (← links)
• Age and neurodegeneration imaging biomarkers in persons with Alzheimer disease dementia (Q40649206) (← links)
• Rhinal hypometabolism on FDG PET in healthy APO-E4 carriers: impact on memory function and metabolic networks (Q41031850) (← links)
• One dataset, many conclusions: BOLD variability's complicated relationships with age and motion artifacts (Q41602512) (← links)
• Dynamic relationships between age, amyloid-β deposition, and glucose metabolism link to the regional vulnerability to Alzheimer's disease (Q41880776) (← links)
• A new data analysis approach for measuring longitudinal changes of metabolism in cognitively normal elderly adults (Q47144813) (← links)
• Healthy brain ageing assessed with 18F-FDG PET and age-dependent recovery factors after partial volume effect correction (Q48419621) (← links)
• Precuneus degeneration in nondemented elderly individuals with APOE ɛ4: Evidence from structural and functional MRI analyses (Q48531560) (← links)
• Topographical APOE ɛ4 Genotype Influence on Cerebral Metabolism in the Continuum of Alzheimer's Disease: Amyloid Burden Adjusted Analysis (Q48547494) (← links)
• Longitudinal Positron Emission Tomography in Preventive Alzheimer's Disease Drug Trials, Critical Barriers from Imaging Science Perspective (Q48609636) (← links)
• Preserved brain metabolic activity at the age of 96 years. (Q48753314) (← links)
• Could Alzheimer's Disease Originate in the Periphery and If So How So? (Q54113689) (← links)
• Predicting Aging of Brain Metabolic Topography Using Variational Autoencoder (Q57176276) (← links)
• Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer's disease (Q57178032) (← links)
• Synergistic interaction between APOE and family history of Alzheimer's disease on cerebral amyloid deposition and glucose metabolism (Q58716110) (← links)
• Spatially Adaptive Varying Correlation Analysis for Multimodal Neuroimaging Data (Q62830996) (← links)
• The effect of ApoE ε4 on longitudinal brain region-specific glucose metabolism in patients with mild cognitive impairment: a FDG-PET study (Q64108331) (← links)
• Dementia spectrum disorders: lessons learnt from decades with PET research (Q64298179) (← links)
• Vascular Dysfunction in Alzheimer's Disease: A Prelude to the Pathological Process or a Consequence of It? (Q64986754) (← links)
• Longitudinal Changes in Serum Glucose Levels are Associated with Metabolic Changes in Alzheimer's Disease Related Brain Regions (Q87877376) (← links)
• Metabolism: A Novel Shared Link between Diabetes Mellitus and Alzheimer's Disease (Q89824008) (← links)
• Spatially Distributed Amyloid-β Reduces Glucose Metabolism in Mild Cognitive Impairment (Q91655785) (← links)
• A Clinical Trial of Transcranial Electromagnetic Treatment in Alzheimer's Disease: Cognitive Enhancement and Associated Changes in Cerebrospinal Fluid, Blood, and Brain Imaging (Q92563404) (← links)
• Differential Effect of APOE Alleles on Brain Glucose Metabolism in Targeted Replacement Mice: An [18F]FDG-μPET Study (Q93332818) (← links)
• Selection of the optimal intensity normalization region for FDG-PET studies of normal aging and Alzheimer's disease (Q96230015) (← links)